Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Total Liabilities (2016 - 2025)

Viking Therapeutics' Total Liabilities history spans 12 years, with the latest figure at $76.7 million for Q4 2025.

  • For Q4 2025, Total Liabilities rose 173.39% year-over-year to $76.7 million; the TTM value through Dec 2025 reached $76.7 million, up 173.39%, while the annual FY2025 figure was $76.7 million, 173.39% up from the prior year.
  • Total Liabilities for Q4 2025 was $76.7 million at Viking Therapeutics, up from $26.4 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $76.7 million in Q4 2025 and bottomed at $8.8 million in Q4 2021.
  • The 5-year median for Total Liabilities is $18.5 million (2023), against an average of $22.4 million.
  • The largest YoY upside for Total Liabilities was 173.39% in 2025 against a maximum downside of 40.3% in 2025.
  • A 5-year view of Total Liabilities shows it stood at $8.8 million in 2021, then surged by 164.38% to $23.2 million in 2022, then decreased by 13.51% to $20.1 million in 2023, then soared by 39.72% to $28.0 million in 2024, then surged by 173.39% to $76.7 million in 2025.
  • Per Business Quant, the three most recent readings for VKTX's Total Liabilities are $76.7 million (Q4 2025), $26.4 million (Q3 2025), and $32.4 million (Q2 2025).